Results 171 to 180 of about 4,994 (256)

Historia Natural de la Infección Crónica por el Virus Hepatitis B

, 2009
En los últimos años se han dado notables pasos en el entendimiento de la biología del virus de la hepatitis B (VHB), su historia natural e inmunopatogénesis, mientras que se implementaron exitosos programas de vacunación universal en diferentes partes del mundo y se hicieron importantes avances en la terapéutica antiviral. Sin embargo, La infección por
Vildózola Gonzales, Herman, Salinas, Jorge Luis   +1 more
openaire   +2 more sources

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source

Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature

, 2006
An association between chronic hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia and non-Hodgkin lymphoma (NHL) has been suggested. However, a causative role of HCV in these conditions has not been established.
Lakatos, Péter László, Horányi, Margit, Abonyi, Margit E., Fischer, Simon, Fekete, Sándor   +4 more
core  

Análise do perfil sorológico de potenciais doadores de órgãos sólidos em Santa Catarina. [PDF]

, 2008
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Amaral, Robson Pereira do
core  

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Diseño de oligonucleótidos que reconocen específicamente el virus de la Hepatitis B.

, 2018
Hepatitis B is a liver infection caused by the potentially deadly Hepatitis B virus (HBV).About 600 000 people die each year from the serious consequences of HBV.
Romero, N.
core  

Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins

Biotechnology Progress, EarlyView.
Virus‐like particle vaccines displaying spike proteins from OC43, HKU1 A, and HKU1 B were evaluated in mice for their ability to elicit antibodies against the spike proteins from OC43, HKU1 A, HKU1 B, and HKU1 C. Abstract Endemic human coronaviruses OC43 and HKU1 cause widespread respiratory infections and can be associated with severe illness in ...
Peter J. Halfmann, Augustine Duffy, Alex Wee, Noah Anderson, Jackson Terrell, Yoshihiro Kawaoka, Ravi S. Kane   +6 more
wiley   +1 more source

Impairments in signaling cascades mediating the progression of liver disease from chronic hepatitis to hepatocellular carcinoma in animal and human models

, 2011
The most common risk factors for chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) include chronic alcohol abuse and infection with hepatitis B (HBV) or hepatitis C (HCV) virus.
Setshedi, Mashiko
core  

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann, Ruy M. Ribeiro, Aurélien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Niveles de anticuerpos posinmunización contra el virus de la hepatitis B

Revista Gaceta Científica HampiKuna
Objetivo: Evaluar la concentración sérica de anticuerpos frente al virus de la hepatitis B en personal del Hospital Nivel II y del CAP III Metropolitano de EsSalud-Huánuco, en Perú. Materiales y métodos: Se trata de una investigación observacional, descriptivo, de carácter longitudinal y con diseño de serie de casos, desarrollada en tres fases ...
openaire   +1 more source